Abstract:In the last years Invasive Aspergillosis (IA) has become the most frequent invasive fungal infection (IFI) affecting children with hematological malignancies. This complication results in the delay of cancer treatment and/or poor prognosis mainly due to late diagnosis and late start of antifungal treatment. Therefore, antifungal prophylaxis and preemptive approaches have been proposed for these patients based on risk factors and local epidemiological data. For this reason, we performed a unicenter, descriptive and prospective study to determine the frequency and clinical course of IA in hospitalized cancer patients with fever and neutropenia. we included events of fever and neutropenia of hospitalized patients with cancer and either with persistent febrile neutropenia (PFN: fever for >96h with total neutrophil count of <500cells/mm3) or profound prolonged neutropenia (PPN: total neutrophil count of 7 days). Informed consent was requested prior inclusion and follow up of these events was performed with weekly measurement of serum galactomannan antigen (until the recovery of neutrophil count), lung computed tomography (CT) and/or sinus and/or central nervous system (CNS) imaging, depending on clinical findings, and if feasible bronchoscopy to obtain bronchioalveolar lavage (BAL) samples. Clinical and laboratory data were obtained; with this information diagnosis of IA was classified as possible, probable, and proven, according to the EORTC/MSG guidelines. This protocol was approved by the hospital's research and ethics committees (INP 041/2021). For data analysis categorical variables were presented as frequencies and numerical variables as median and range. Statistical analysis was made with X 2 and U Mann Whitney tests. Seventy events were included, 14 (20%) had IA diagnosis; 2 possible, 11 probable and 1 proved. Median of age was 10.2y (5.5 – 17) and 64.3% were male. Acute lymphoblastic leukemia was the main oncologic diagnosis (71.4%), 35.7% during induction phase; followed by acute myeloblastic leukemia (21.4%). 92.9% of events with IA presented as PFN (p=0.001) with a fever duration of 3.5 days (1-8) (p=0.004). Pulmonary disease was evident in all events with IA, two had disseminated infection. In 5/14 events serum galactomannan antigen was positive in the first measurement. Only 8 events underwent bronchoscopy: BAL was positive in 6 and 4 had positive culture with Aspergillus spp. Lung CT scan showed different findings, lobar/segmental consolidation and nodule with halo sign were the most common; 85.7% of cases presented with more than one radiological sign (p=0.003). Voriconazole monotherapy was given to 78.5% of IA cases and 21.4% required combined antifungal therapy (added caspofungine or liposomal amphotericin B) due to disseminated disease or severe clinical course. Intensive care admission resulted with statistical significance for the events with diagnosis of IA (64.3% p= 0.019). Within the IA events survival at 60 days was of 78.6%. Frequency of IA was high among our high risk cancer patients. This study demonstrates the importance of a complete work up for invasive fungal infection in high-risk patients with persistent febrile neutropenia. The information obtained is of great use for the implementation of pre-emptive approaches and antifungal prophylaxis in this patient population.

Global motion segmentation for mid-level representation of moving images

Antifungal resistance mechanisms of Aspergillus.

Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients

Invasive aspergillosis: A comprehensive review

Why are so many cases of invasive aspergillosis missed?

Utility of CT Assessment in Hematology Patients with Invasive Aspergillosis: a Post-Hoc Analysis of Phase 3 Data

Effects Of Feeding Different Levels Of Distillery Yeast Biomass On Growth Performance In Broiler Chickens

An immunocompetent lady with invasive aspergillosis presenting as disseminated lesions: a case report

Clinical insights into Invasive Aspergillosis in Mexican children with cancer

Diagnosis and Treatment of Invasive Aspergillosis Caused by Non- fumigatus Aspergillus spp

Invasive pulmonary and central nervous system aspergillosis in a child: A case report and literature review

Invasive pulmonary aspergillosis in patients with acute-on-chronic liver failure.

Invasive Aspergillosis in solid‐organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

[The Clinical Monitoring of Invasive Aspergillosis in Surgical Intensive Care Unit During 10 Years].

Invasive Pulmonary Aspergillosis in Patients with Antineutrophil Cytoplasmic Antibody Associated Vasculitis.

Abdominal Aspergillosis – an Underdiagnosed Disease? Three Cases of Abdominal Aspergillosis in Severely Immunocompromised Infants

Risk Factors and Outcomes of Invasive Aspergillosis in Kidney Transplant Recipients: A Case-Control Study of United States Renal Data System Data

A plasmid for the quantification of the CD21 human interferon-alpha receptor expression by PCR.

Negative (1,3)-Β-d-glucan and Elevated White Blood Cells Combined Procalcitonin Masquerading As Severe Pneumonia Eventually Diagnosed As Invasive Pulmonary Aspergillosis Proven by Bronchoalveolar Lavage Fluid Culture in a Diabetes Patient: a Case Report and Literature Review

Disseminated multi-organ aspergillosis with acute cerebral infarction in a patient with myelodysplastic syndrome. A case report.

Clinical Findings in 19 Cases of Invasive Pulmonary Aspergillosis with Liver Cirrhosis